Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) have been given a consensus recommendation of “Buy” by the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $45.08.
A number of equities research analysts have weighed in on the stock. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $40.00 price target on shares of Viridian Therapeutics in a research report on Thursday, March 9th. Needham & Company LLC restated a “buy” rating and issued a $47.00 price objective on shares of Viridian Therapeutics in a report on Monday, April 10th. Stifel Nicolaus assumed coverage on shares of Viridian Therapeutics in a report on Wednesday, March 29th. They issued a “buy” rating and a $49.00 price objective for the company. Wells Fargo & Company began coverage on shares of Viridian Therapeutics in a report on Monday, April 17th. They issued an “overweight” rating and a $46.00 price objective for the company. Finally, JMP Securities lowered their price target on shares of Viridian Therapeutics from $46.00 to $44.00 in a report on Wednesday, May 10th.
Insider Buying and Selling at Viridian Therapeutics
In other news, CEO Scott Dunseth Myers acquired 5,500 shares of the company’s stock in a transaction on Monday, March 13th. The shares were bought at an average cost of $29.15 per share, with a total value of $160,325.00. Following the purchase, the chief executive officer now owns 255,500 shares of the company’s stock, valued at approximately $7,447,825. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Viridian Therapeutics news, CEO Scott Dunseth Myers bought 5,500 shares of the company’s stock in a transaction on Monday, March 13th. The stock was purchased at an average cost of $29.15 per share, for a total transaction of $160,325.00. Following the acquisition, the chief executive officer now owns 255,500 shares of the company’s stock, valued at approximately $7,447,825. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Lara Meisner sold 29,971 shares of the firm’s stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $29.07, for a total transaction of $871,256.97. The disclosure for this sale can be found here. 4.48% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Viridian Therapeutics
Viridian Therapeutics Stock Performance
NASDAQ:VRDN opened at $23.43 on Monday. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $27.03 and its 200-day moving average price is $28.37. Viridian Therapeutics has a twelve month low of $9.84 and a twelve month high of $39.00. The company has a market cap of $1.01 billion, a P/E ratio of -5.03 and a beta of 0.95.
Viridian Therapeutics (NASDAQ:VRDN – Get Rating) last issued its earnings results on Tuesday, May 9th. The company reported ($1.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.61). Viridian Therapeutics had a negative return on equity of 84.78% and a negative net margin of 7,329.23%. The firm had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same period last year, the firm earned ($0.98) earnings per share. Viridian Therapeutics’s revenue for the quarter was down 54.6% on a year-over-year basis. On average, sell-side analysts forecast that Viridian Therapeutics will post -4.43 earnings per share for the current fiscal year.
Viridian Therapeutics Company Profile
Viridian Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis.
- Get a free copy of the StockNews.com research report on Viridian Therapeutics (VRDN)
- MarketBeat Week in Review – 5/8 – 5/12
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.